News ReleaseView printer-friendly version << Back
Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
PARSIPPANY, N.J., April 8, 2011 /PRNewswire via COMTEX/ --
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX), an emerging specialty pharmaceutical company, today announced James Scibetta, chief financial officer, is scheduled to present at the BioCentury Future Leaders in the Biotech Industry Conference on Friday, April 15, 2011, at 11:30 a.m. EDT being held at the Millennium Broadway Hotel & Conference Center in New York City. Mr. Scibetta is expected to present an overview of the company.
A live audio webcast of Pacira's presentation can be accessed by visiting the investors section of the company's website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
Pacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, manufacture and commercialization of novel pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. In December 2010, Pacira announced that its New Drug Application (NDA) for EXPAREL, the company's most advanced investigational product candidate, had been accepted for filing by the U.S. Food and Drug Administration (FDA). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of July 28, 2011 for the review of the EXPAREL NDA. EXPAREL is a bupivacaine-based product and has completed extensive Phase 3 clinical development for postoperative analgesia by infiltration. EXPAREL consists of bupivacaine encapsulated in DepoFoam, which is designed to address the limitations of widely used medications by enhancing their dosing and/or administration profile. Additional information about Pacira is available at www.pacira.com.
Pacira Pharmaceuticals, Inc.
James S. Scibetta, 973-254-3560
Pure Communications Inc.
Jennifer Beugelmans, 646-596-7473
SOURCE Pacira Pharmaceuticals, Inc.